Oncology 32: 221-222 (1975)

Hydrazine Sulfate and Preneoplastic Exfoliated Cells Ralph L. Norman US Army Missile Command, Redstone Arsenal, Ala.

Key Words. Hydrazine sulfate • Preneoplastic exfoliated cells

In 1968, Gold (1) proposed that cancer cachexia results from a host system­ ic energy-losing cycle which involves cancer glycolysis and host gluconeogenesis. This understanding of the energy-loss mechanism seen with the progression of cancer came from an extensive array of in vitro and in vivo experimentation. Further research by Gold (2 -4 ) and Ray et al. (5) indicates inhibition of this energy-losing cycle by hydrazine sulfate and other agents at the phosphoenolpyruvate carboxykinase level with most encouraging tests on animals (3, 4) and clinical trials on humans (2, 3). Beyond weight loss, Gold (2 -4 ) reports that hydrazine sulfate exhibits no toxic effects and only a few mild side effects. Immediate patient improvements are return of appetite, vigor, strength and positive mental outlook. At what point in its morphological transition a preneoplastic cell begins this energy-losing cycle appears unestablished. However, obviously at some point each preneoplastic or neoplastic cell must enter this cycle. Since a preneoplastic exfoliated cell smear indicates a morphological transition which is malignant at its completion, it is postulated that hydrazine sulfate could arrest this transition and prove a preferable alternative to surgery. The previously cited experiments and positive clinical trials on malignancy are a sufficient scientific foundation to warrant clinical tests to determine if hydrazine sulfate will arrest the progress of preneoplastic morphological transitions.

Downloaded by: King's College London 137.73.144.138 - 1/30/2019 2:54:53 AM

Abstract. Animal experiments and most encouraging clinical trials substantiate that hydrazine sulfate inhibits the paraneoplastic systemic energy-losing cycle. The question arises: could hydrazine sulfate offer an alternative to surgery for patients with preneoplastic exfoliated cells? Research data indicate that clinical trials are appropriate.

Norman

222

References 1 2 3 4

5

Gold, J.: Proposed treatment of cancer by inhibition of gluconeogenesis. Oncology 22: 185-207 (1968). Gold, J.: Cancer therapy with hydrazine sulfate. Presentation to German Society for Medical Tumor Therapy, Baden-Baden 1973. Gold, J.: Cancer cachexia and gluconeogenesis. N.Y. Acad. Sci. Ann. 230: 102-110 (1974). Gold, J.: Inhibition of gluconeogenesis at the phosphoenolpyruvate carboxykinase and pyruvate carboxylase reactions, as a means of cancer chemotherapy. Oncology 29: 74-89 (1974). Ray, P.D.: Hanson, R.L., and Lardy, H.A.: Inhibition by hydrazine of gluconeogenesis in the rat. J. biol. Chem. 245: 690-696 (1970).

Downloaded by: King's College London 137.73.144.138 - 1/30/2019 2:54:53 AM

Ralph L. Norman, ARPASO Project Manager, US Army Missile Command, Redstone Arsenal, AL 35809 (USA)

Hydrazine sulfate and preneoplastic exfoliated cells.

Animal experiments and most encouraging clinical trials substantiate that hydrazine sulfate inhibits the paraneoplastic systemic energy-losing cycle. ...
191KB Sizes 0 Downloads 0 Views